(Reuters Health) – Even though diabetes rates are almost twice as high in black people as in whites, black patients may be far less likely to be included in drug safety trials, a recent study suggests.
Since 2008, the U.S. Food and Drug Administration has required that new glucose-lowering medications for diabetes be tested for cardiovascular safety, which may differ based on patients’ race or ethnicity, researchers note in The Lancet Diabetes and Endocrinology.
Read Next
